Use of technetium-99m hexamethylpropylene amine oxime SPET for the study of cerebral blood flow reactivity after acetazolamide infusion in patients with Behcet's disease

European Journal of Nuclear Medicine

Volumn 27, Issue 6, 2000, Pages 700-706

  Pupi, Alberto ^a,c   Sestini, Stelvio ^a   De Cristofaro, Maria Teresa R ^a   Emmi, Lorenzo ^b   Marchione, Teresa ^b   Salvati, Gaetano ^b   Gobbi, Francesca Li ^b   Massacesi, Luca ^b   Meldolesi, Ugo ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Nuclear Medicine Unit   (Italy)

Author keywords

Acetazolamide; Behcet's disease; Diaschisis; Tomography emission computed

Indexed keywords

ACETAZOLAMIDE; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M;

ADULT; ARTICLE; BEHCET DISEASE; BRAIN BLOOD FLOW; BRAIN PERFUSION; CLINICAL ARTICLE; DEAFFERENTATION; DRUG UPTAKE; FEMALE; GRAY MATTER; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VASCULITIS;

ACETAZOLAMIDE; ADULT; BEHCET SYNDROME; CEREBROVASCULAR CIRCULATION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; TECHNETIUM TC 99M EXAMETAZIME; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0034043259     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050565     Document Type: Article

References (37)

1. 1. O'Duffy JD. Behçet's disease. Curr Opin Rheumatol 1994; 6: 39-43.
2. 2. Serdaroglu P. Behçet's disease and the nervous system. J Neurol 1998; 254: 197-205.
3. 3. Kaklamani VG, Vaiopoulos G, Kaklamanis P. Behçet's disease. Semin Arthritis Rheum 1998; 27: 197-217.
4. 4. Wolf SM, Shotland DL, Phillips LL. Involvement of nervous system in Behçet's syndrome. Arch Neurol 1965; 12: 315-325.
5. 5. O'Duffy JD, Goldstein NP. Neurological involvement in seven patients with Behçet's disease. Am J Med 1976; 61: 170-178.
6. 6. Fadli ME, Youssef MM. Neuro-Behçet's syndrome in the United Arab Republic. Eur Neurol 1973; 9: 76-89.
7. 7. Serdaroglu P, Yazici H, Ozdemir C, Yurdakul S, Bahar S, Atkin E. Neurologic involvement in Behçet's syndrome: a prospective study. Arch Neurol 1989; 46: 265-269.
8. 8. Watanabe N, Seto H, Sato S, Simizu M, Wu Y, Kageyama M, Nomura K, Kakishita M. Brain SPECT with neuro-Behçet disease. Clin Nucl Med 1995; 20: 61-64.
9. 9. Matsuda H, Uesugi H, Yagishita A. SPECT Imaging in a patient with neuro-Behçet disease. Clin Nucl Med 1995; 6: 559-560.
10. 10. Markus HS, Bunker CB, Kouris K, Costa DC, Harrison MJ. RCBF abnormalities detected, and sequentially followed, by SPECT in neuro-Behçet's syndrome with normal CT and MRI. J Neurol 1992; 239: 363-366.
11. 11. Trotta F, Bajochi G, Colamussi P, Sandri G, Ciancio G, Tola MR, Menegale G, Cittanti C, Giganti M, Piffanelli A. Cerebral hypoperfusion detected by SPET in early neuro-Behçet syndrome. Nucl Med Commun 1998; 19: 777-780.
12. 12. Kao CH, Lan JL, GhangLai SP, Chieng PU. Technetium-99m-HMPAO SPECT and MRI of brain in patients with neuro-Behçet's syndrome. J Nucl Med 1998; 39: 1707-1710.
13. 13. Garcia-Burillo A, Castell J, Fraile M, Jacas C, Vilardell M, Ortega D, Bosch JA. Technetium-99m-HMPAO brain SPECT in Behçet's disease. J Nucl Med 1998; 39: 950-954.
14. 14. Avci O, Kutluay E, Argon M, Erdem S, Tahsin Gunes A. Subclinical cerebral involvement in Behçet's disease: a SPECT study. Eur J Neurol 1998; 5: 49-53.
15. 15. Arai T, Mizukami K, Sasaki M, Tanaka Y, Shiraishi H, Horiguchi H, Ogata T. Clinicopathological study on a case of neuro-Behçet disease: in special reference to MRI, SPECT and neuropathological findings. Jpn J Psychiatry 1994; 48: 77-84.
16. 16. Yudd AP, Van Heertum LR, Masdeu JC. Interventions and functional brain imaging. Semin Nucl Med 1991; 21: 153-158.
17. 17. International Study Group for Behçet's disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-1080.
18. 18. Hattori N, Yonekura Y, Tanaka F, Fujita T, Wang J, Ishizu K, Okazawa H, Tamaki N, Konishi J. One-day protocol for cerebral perfusion reserve with acetazolamide. J Nucl Med 1996; 37: 2057-2061.
19. 19. Weisner PS, Bower GR, Dollimore LA, Forster AM, Higley B, Storey AE. A method for stabilising technetium-99m exametazime prepared from a commercial kit. Eur J Nucl Med 1993; 20: 661-666.
20. 20. Formiconi AR, Pupi A, Passeri A. Compensation of spatial system response in SPECT with conjugate gradient reconstruction technique. Phys Med Biol 1989; 34: 69-84.
21. 21. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 1978; NS-25: 638-643.
22. 22. Imran MB, Kawashima R, Awata S, Sato K, Kinomura S, Ono S, Yoshioka S, Sato M, Fukuda H. Parametric mapping of cerebral blood flow deficits in Alzheimer's disease: a SPECT study using HMPAO and image standardization technique. J Nucl Med 1999; 40: 244-249.
23. 23. Robb RA, Hanson DP. ANALYZE: a software system for biomedical image analysis. Proceedings of the First Conference on Visualisation in Biomedical Computing, Atlanta, Ga., May 22-25, 1990, 507-518.
24. 20 positron emission tomography. Eur J Nucl Med 1996; 23:683-689.
25. 25. Knapp WH, Dannemberg C, Marshall B, Zedlick D, Loschmann K, Bettin S, Barthel H, Seese A. Changes in local cerebral blood flow by neuroactivation and vasoactivation in patients with impaired cognitive function. Eur J Nucl Med 1996; 23: 878-888.
26. 26. Von Monakov C. Experimentelle und pathologish-anatomische Untersuchungen Fiber die Haubenregion, den Sehlhfigel und der Regio subthalamica. Arch Psychiatr 1885;27:1.
27. 27. Kempinsky WH. Experimental study of distal effects of acute focal injury. Arch Neurol Psychiatry 1958; 79: 376-389.
28. 28. Bakshi R, Miletich RS, Kinkel PR, Emmet ML, Kinkel WR. High resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis. J Neuroimaging 1998; 8:228-234.
29. 29. De Cristofaro MT, Mascalchi M, Pupi A, Nencini P, Formiconi AR, Inzitari D, Dal Pozzo G, Meldolesi U. Subcortical arteriosclerotic encephalopathy: single photon emission computed tomography-magnetic resonance imaging correlation. Am J Physiol Imaging. 1990; 5: 68-74.
30. 30. Yao H, Sadoshima S, Ibayashi S, Kuwabara Y, Ichiya Y, Fujishima M. Leukoaraiosis and dementia in hypertensive patients. Stroke 1992; 23: 1673-1677.
31. 31. Sabri O, Ringelstein E, Hellwig D, Scheider R, Schreckenberger M, Kaiser H, Mull M, Buell U. Neuropsychological impairment correlates with hypoperfusion and hypometabolism but not with severity of white matter lesions on MRI in patients with cerebral microangiopathy. Stroke 1999; 30: 556-566.
32. 32. Tatemichi TK, Desmond DW, Prohovnik I, Cross DT, Gropen TI, Mohr JP, Stern Y. Confusion and memory loss from capsular genu infarction: a thalamocortical disconnection syndrome? Neurology 1992; 42: 1966-1979.
33. 33. Lakhanpal SH, Tani K, Lie JT, Katoh K, Ishigatsubo Y, Ohokubo T. Pathologic features of Behçet's syndrome: a review of Japanese autopsy registry data. Hum Pathol 1985; 16: 790-795.
34. 34. Tali ET, Atilla S, Keskin T, Simonson T, Isik S, Yuh WT. MRI in neuro-Behçet's disease. Neuroradiology 1997; 39: 2-6.
35. 35. Gerber S, Biondi A, Dormont D, Wechsler B, Marsault C. Long-term MR follow-up of cerebral lesions in neuro-Behçet's disease. Neuroradiology 1996; 38: 761-768.
36. 36. Morrissey SP, Miller DH, Hermaszewski R, Rudge P, MacManus DG, Kendall B, McDonald WI. Magnetic resonance imaging of the central nervous system in Behçet's disease. Eur Neurol 1993; 33: 287-293.
37. 37. Meyer JS, Obara K, Muramatsu K. Diaschisis. Neurol Res 1993; 15: 362-366